The Japan myasthenia gravis treatment market is anticipated to witness considerable growth during the forecast period. Myasthenia gravis is an autoimmune neuromuscular disorder which is triggered by defect in neuromuscular transmission. The autoimmune disorder is very responsive to treatment, and the symptoms are constantly coming to be extra efficient. The treatments of myasthenia Gravis are needed for improving the health condition of individuals, and the quality of life.
Rise in prevalence of myasthenia gravis and increase in awareness regarding treatments of the disorder is a significant factor driving the growth of the Japan myasthenia gravis treatment market. Furthermore, with improved medical diagnosis, there is surge in need for advanced treatment options, which is expected to augment the growth of the market. In addition, the advent of monoclonal antibodies, combined with the different benefits related to them, such as high selectivity and long-lasting activity, is expected to provide profitable opportunities during the projection duration.
Furthermore, rise in financial investments by the pharmaceutical companies in R&D activities are anticipated to spur the need for myasthenia gravis disorder medicines in the Japan myasthenia gravis treatment market.
On the other hand, side effects of the drugs used for dealing with myasthenia gravis and lack of technical skilled expertise are expected to hamper the market growth.
Conversely, the authorization of license for new treatment options for myasthenia gravis is expected to offer lucrative opportunities for the growth of the Japan myasthenia gravis treatment market. For instance, in 2017, the united state FDA granted AbbVie's new drug application (NDA) for Rituxan (rituximab) as an intravenous (IV) infusion 100 mg plus glucocorticoid, for the treatment of adult patients with moderately to severely active myasthenia gravis (MG).
The Japan myasthenia gravis treatment market is segmented into drug class, age group, and distribution channel. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin, and others. Monoclonal antibodies (MABs) are medications that are designed to engage specifically with certain kinds of cells, which can be beneficial in treating autoimmune disorders, such as myasthenia gravis. Intravenous immunoglobulin (IVIG) treatment is just one of the most usual treatments for dealing with myasthenia gravis. By age group, the market is divided into below 55 years and above 55 years. The above 55 years segment has a higher frequency of myasthenia gravis, as the disease is more probable to affect older people. Depending on distribution channel, the market is classified into hospital pharmacies, drug stores and retail pharmacies and online providers.
The Porter's five force analysis is a model, which analyzes the competitive scenario of the industry and role of each stakeholder. It includes the bargaining power of buyers, the bargaining power of suppliers, the threat of substitutes, the threat of new entrants, and the competition among competitive rivalry.
The threat of new entrants is low due to the existence of patent legislation and the existence of major players in the market. The threat of substitutes is low due to the accessibility of a minimal number of treatments available in the market. The bargaining power of suppliers is low due to the presence of a limited number of suppliers in the market. The bargaining power of buyers is low due to the limited availability of treatment options. The intensity of competitive rivalry is high due to the several significant players in the market.
The Japan myasthenia gravis treatment market is characterized by the increase in R&D activities by the pharmaceutical business looking to establish new alternatives treatments for the condition. In addition, upsurge in patent issuances for the treatments of myasthenia gravis is fueling the growth of the market.
Key players included in the report are Astellas Pharma, GlaxoSmithKline, Takeda Pharmaceutical, Daiichi Sankyo, Teva Pharmaceutical Industries, Torii Pharmaceutical, UCB, Merck & Co., Pfizer, Genzyme Corporation
The myasthenia gravis treatment market is segmented into drug class, and distribution channel. In terms of drug class, it is bifurcated into monoclonal antibodies, intravenous immunoglobulin, others. Based on the distribution channel, below 55 Years, above 55 Years.
Rise in prevalence of myasthenia gravis and increase in awareness regarding treatments of the disorder is a significant factor driving the growth of the Japan myasthenia gravis treatment market. Furthermore, with improved medical diagnosis, there is surge in need for advanced treatment options, which is expected to augment the growth of the market. In addition, the advent of monoclonal antibodies, combined with the different benefits related to them, such as high selectivity and long-lasting activity, is expected to provide profitable opportunities during the projection duration.
Furthermore, rise in financial investments by the pharmaceutical companies in R&D activities are anticipated to spur the need for myasthenia gravis disorder medicines in the Japan myasthenia gravis treatment market.
On the other hand, side effects of the drugs used for dealing with myasthenia gravis and lack of technical skilled expertise are expected to hamper the market growth.
Conversely, the authorization of license for new treatment options for myasthenia gravis is expected to offer lucrative opportunities for the growth of the Japan myasthenia gravis treatment market. For instance, in 2017, the united state FDA granted AbbVie's new drug application (NDA) for Rituxan (rituximab) as an intravenous (IV) infusion 100 mg plus glucocorticoid, for the treatment of adult patients with moderately to severely active myasthenia gravis (MG).
The Japan myasthenia gravis treatment market is segmented into drug class, age group, and distribution channel. On the basis of drug class, the market is categorized into monoclonal antibodies, intravenous immunoglobulin, and others. Monoclonal antibodies (MABs) are medications that are designed to engage specifically with certain kinds of cells, which can be beneficial in treating autoimmune disorders, such as myasthenia gravis. Intravenous immunoglobulin (IVIG) treatment is just one of the most usual treatments for dealing with myasthenia gravis. By age group, the market is divided into below 55 years and above 55 years. The above 55 years segment has a higher frequency of myasthenia gravis, as the disease is more probable to affect older people. Depending on distribution channel, the market is classified into hospital pharmacies, drug stores and retail pharmacies and online providers.
The Porter's five force analysis is a model, which analyzes the competitive scenario of the industry and role of each stakeholder. It includes the bargaining power of buyers, the bargaining power of suppliers, the threat of substitutes, the threat of new entrants, and the competition among competitive rivalry.
The threat of new entrants is low due to the existence of patent legislation and the existence of major players in the market. The threat of substitutes is low due to the accessibility of a minimal number of treatments available in the market. The bargaining power of suppliers is low due to the presence of a limited number of suppliers in the market. The bargaining power of buyers is low due to the limited availability of treatment options. The intensity of competitive rivalry is high due to the several significant players in the market.
The Japan myasthenia gravis treatment market is characterized by the increase in R&D activities by the pharmaceutical business looking to establish new alternatives treatments for the condition. In addition, upsurge in patent issuances for the treatments of myasthenia gravis is fueling the growth of the market.
Key players included in the report are Astellas Pharma, GlaxoSmithKline, Takeda Pharmaceutical, Daiichi Sankyo, Teva Pharmaceutical Industries, Torii Pharmaceutical, UCB, Merck & Co., Pfizer, Genzyme Corporation
The myasthenia gravis treatment market is segmented into drug class, and distribution channel. In terms of drug class, it is bifurcated into monoclonal antibodies, intravenous immunoglobulin, others. Based on the distribution channel, below 55 Years, above 55 Years.
Key Benefits For Stakeholders
- Enable informed decision-making process and offer market analysis based on current market situation and estimated future trends.
- Analyze the key strategies adopted by major market players in Japan Myasthenia Gravis Treatment Market.
- Assess and rank the top factors that are expected to affect the growth of japan Myasthenia Gravis Treatment Market.
- Top Player positioning provides a clear understanding of the present position of market players.
- Identify key investment pockets for various offerings in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Product Benchmarking / Product specification and applications
- Upcoming/New Entrant by Regions
- Patient/epidemiology data at country, region, global level
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- SWOT Analysis
Key Market Segments
By Age group
- Below 55 years
- Above 55 years
By Drug class
- Monoclonal antibodies
- Intravenous immunoglobulin
- Others
By Distribution channel
- Hospital pharmacies
- Drug store and retail pharmacies
- Online providers
- Key Market Players
- Astellas Pharma
- GlaxoSmithKline
- Takeda Pharmaceutical
- Daiichi Sankyo
- Teva Pharmaceutical Industries
- Torii Pharmaceutical
- UCB
- Merck & Co.
- Pfizer
- Genzyme Corporation
Please note:
- Online Access price format is valid for 60 days access. Printing is not enabled.
- PDF Single and Enterprise price formats enable printing.
Table of Contents
CHAPTER 1: INTRODUCTION
CHAPTER 2: EXECUTIVE SUMMARY
CHAPTER 3: MARKET OVERVIEW
CHAPTER 4: JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
CHAPTER 5: JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
CHAPTER 6: JAPAN MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
CHAPTER 7: COMPETITIVE LANDSCAPE
CHAPTER 8: COMPANY PROFILES
List of Tables
List of Figures
Companies Mentioned
- Astellas Pharma
- GlaxoSmithKline
- Takeda Pharmaceutical
- Daiichi Sankyo
- Teva Pharmaceutical Industries
- Torii Pharmaceutical
- UCB
- Merck & Co.
- Pfizer
- Genzyme Corporation
Methodology
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.
LOADING...
